Tyra Biosciences (TYRA) Income from Continuing Operations (2020 - 2026)
Tyra Biosciences (TYRA) reported Income from Continuing Operations of 39305000.0 for Q1 2026, down 39.64% on a YoY basis from 65119655.95 in Q1 2025, and down 16.17% quarter-over-quarter from 33834000.0 in Q4 2025.
Tyra Biosciences (TYRA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tyra Biosciences has reported Income from Continuing Operations for 7 years, with the latest figure at 39305000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 39.64% year-over-year to 39305000.0; the trailing twelve-month figure through Mar 2026 stood at 131105000.0 (down 35.95% YoY), and the FY2025 full-year result was 119947000.0, down 38.7% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 39305000.0, down from 33834000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 11881000.0 in Q1 2023, with the low at 39305000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 21777882.35 across 5 years, with a median of 21152000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 252.25% — and 2023, when it rose 19.86%.
- Tyra Biosciences' Income from Continuing Operations stood at 12895000.0 in 2022, then plunged by 77.05% to 22830000.0 in 2023, then slipped by 12.01% to 25571000.0 in 2024, then slumped by 32.31% to 33834000.0 in 2025, then retreated by 16.17% to 39305000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 39305000.0 (Q1 2026), 33834000.0 (Q4 2025), and 29868000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - | -39.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.31 Mn |
| Dec 31, 2025 | -33.83 Mn |
| Sep 30, 2025 | -29.87 Mn |
| Jun 30, 2025 | -28.10 Mn |
| Mar 31, 2025 | -28.15 Mn |
| Dec 31, 2024 | -25.57 Mn |
| Sep 30, 2024 | -24.02 Mn |
| Jun 30, 2024 | -18.70 Mn |
| Mar 31, 2024 | -18.19 Mn |
| Dec 31, 2023 | -22.83 Mn |
| Sep 30, 2023 | -21.15 Mn |
| Jun 30, 2023 | -13.29 Mn |
| Mar 31, 2023 | -11.88 Mn |
| Dec 31, 2022 | -12.90 Mn |
| Sep 30, 2022 | -12.52 Mn |
| Jun 30, 2022 | -15.10 Mn |
| Mar 31, 2022 | -14.83 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -6.64 Mn |
| Jun 30, 2021 | -5.51 Mn |